retatrutide latest trial results Results: How Much Weight Can You Lose & How Quick? retatrutide triple hormone receptor agonist

It is licensed in the UK as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management

While these providers still account for less than 20% of overall GLP-1 volume, their adoption signals a major shift in how these powerful drugs are perceived as the prescribing audience expands

US President Donald Trump announces agreements with drug makers Eli Lilly and Novo Nordisk.

The data were analyzed using both mean differences (MDs) and standardized mean differences (SMDs) with 95% CIs and odds ratios (ORs) with 95% CIs

Examine what to expect from the first month of taking GLP-1 medications, the side effects you may encounter, and what to report back to your physician.

Over the past year, GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound have dramatically reshaped the conversation around weight